Emerging TSPO-PET Radiotracers for Imaging Neuroinflammation: A Critical Analysis.

Autor: Cumbers GA; School of Chemistry, Faculty of Science, The University of Sydney, New South Wales, Australia., Harvey-Latham ED; School of Chemistry, Faculty of Science, The University of Sydney, New South Wales, Australia., Kassiou M; School of Chemistry, Faculty of Science, The University of Sydney, New South Wales, Australia. Electronic address: michael.kassiou@sydney.edu.au., Werry EL; School of Chemistry, Faculty of Science, The University of Sydney, New South Wales, Australia; Central Clinical School, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia., Danon JJ; School of Chemistry, Faculty of Science, The University of Sydney, New South Wales, Australia.
Jazyk: angličtina
Zdroj: Seminars in nuclear medicine [Semin Nucl Med] 2024 Nov; Vol. 54 (6), pp. 856-874. Date of Electronic Publication: 2024 Oct 29.
DOI: 10.1053/j.semnuclmed.2024.09.007
Abstrakt: The translocator protein (TSPO) is a biomarker for imaging neuroinflammation via Positron Emission Tomography (PET) across a broad range of CNS conditions. Most clinically used PET ligands targeting TSPO have limitations, including high lipophilicity and off-target binding or poor binding to a mutated TSPO isoform present in up to 30% of the population. Research efforts over the past decade have focused on development of improved TSPO PET radiotracers that overcome these limitations. This review provides a critical analysis of the development and validation of these so-called "third-generation" radiotracers in clinical and preclinical settings. We also offer our perspective on the future directions of TSPO PET imaging, including recommendations for overcoming current challenges and capitalizing on emerging opportunities in molecular imaging for neuroinflammatory diseases.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jonathan Danon reports financial support was provided by National Health and Medical Research Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: